Terasaki P I, Vredevoe D L, Porter K A, Mickey M R, Marchioro T L, Faris T D, Herrmann T J, Starzl T E
Transplantation. 1966 Nov;4(6):688-99. doi: 10.1097/00007890-196611000-00004.
An attempt was made to determine whether 36 long-term kidney homograft recipients and their donors were compatible for 7 major leukocyte groups. It was found that 21 of these recipients were surviving 2 to 3 years in spite of incompatibility for 1 or 2 major leukocyte antigens. Survival of mismatched grafts does not itself indicate that the antigens being measured are not transplantation antigens, for it was shown that the 15 recipients with no groups of mismatch were clinically superior to those with group incompatibilities. Moreover, histopathologic scores given to biopsy specimens taken 2 to 3 years after transplantation were significantly correlated with the number of group mismatches. Because the leukocyte groups were determined by cytotoxicity reactions of peripheral blood lymphocytes, the results may have been influenced considerably by chimerism in chronically dialyzed uremic patients or change in lymphocyte antigenicity or susceptibility to lysis upon prolonged immunosuppressive treatment. Although the possibility of these complications could not be ruled out in all instances, it was shown that 52 dialyzed uremic patients and 49 patients who had been treated with immunosuppression for over 1 year did not possess more or less antigens than a random population of normal individuals. It is concluded that: (1) the major leukocyte antigens are histocompatibility antigens and (2) since survival can be attained at times despite mismatches for these groups, the antigens are of intermediate strength and kidney homograft rejection may occur if excessive numbers of antigens are incompatible or if particular combinations of antigens are mismatched.
研究人员试图确定36名长期肾移植受者及其供者是否匹配7种主要白细胞组。结果发现,其中21名受者尽管在1种或2种主要白细胞抗原上不匹配,但仍存活了2至3年。不匹配移植肾的存活本身并不表明所检测的抗原不是移植抗原,因为研究表明,没有抗原不匹配组的15名受者在临床上优于存在组不匹配的受者。此外,移植后2至3年获取的活检标本的组织病理学评分与组不匹配的数量显著相关。由于白细胞组是通过外周血淋巴细胞的细胞毒性反应来确定的,因此慢性透析尿毒症患者的嵌合体现象、淋巴细胞抗原性的改变或长期免疫抑制治疗后对裂解的易感性可能会对结果产生相当大的影响。尽管在所有情况下都不能排除这些并发症的可能性,但研究表明,52名透析尿毒症患者和49名接受免疫抑制治疗超过1年的患者,其抗原数量与正常个体的随机群体相比并没有更多或更少。研究得出以下结论:(1)主要白细胞抗原是组织相容性抗原;(2)由于有时尽管这些组存在不匹配仍可实现存活,因此这些抗原强度中等,如果大量抗原不匹配或特定抗原组合不匹配,可能会发生肾移植排斥反应。